Pediatrix Medical Group, Inc. MD R2KR3KPHARMA
Company Overview
Pediatrix Medical Group, Inc., together with its subsidiaries, provides newborn, maternal-fetal, and other pediatric subspecialty care services in the United States. The company offers clinical care to babies born prematurely or with complications within specific units at hospitals, primarily NICUs, through its network of affiliated neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; and inpatient and office-based clinical care to expectant mothers and unborn babies through its affiliated maternal-fetal medicine subspecialists, obstetricians and other clinicians, maternal-fetal medicine nurse practitioners, certified nurse midwives, sonographers, and genetic counselors. It also provides other pediatric subspecialty care, including pediatric intensivists, pediatric hospitalists, and pediatric surgeons; support services in other areas of hospitals comprising pediatric emergency room, labor and delivery area, and nursery and pediatric departments; a newborn hearing screening program. The company was formerly known as MEDNAX, Inc. and changed its name to Pediatrix Medical Group, Inc. in July 2022. Pediatrix Medical Group, Inc. was founded in 1979 and is based in Sunrise, Florida.
Why Investors Should Care
Generates a return on equity of 20.4%, reflecting efficient use of shareholder capital.
Trades at a P/E of 12.9, below the sector median of 25.2.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $1.91B (-4.9% YoY); net profit $165.39M.
- Trailing 12 Months Year-on-year growth — revenue +4.0%, earnings +6.5%.
- 5-Year Trend Long-term compounding — revenue CAGR -6.2%, profit CAGR -0.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -6.16% |
| 1 Year: | 4.00% |
Compounded Profit Growth
| 5 Years: | -0.14% |
| 1 Year: | 6.50% |
Stock Price Performance
| 1 Year: | +74.39% |
| 6 Months: | +36.86% |
| 3 Months: | +19.55% |
| 1 Month: | +1.96% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)57.42 · Neutral
P/E of 12.93 is below the sector median of 25.17 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 20.4%.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -6.2% CAGR over 5 years.
- Earnings shrank at -0.1% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MD Pediatrix Medical Group, Inc. R2KR3KPHARMA | 27.03 | 12.93 | $2.20B | 0.00% | 12.93% | 20.39% | -6.16% | -0.14% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 835.60M | 842.94M | 868.95M | 910.82M | 852.63M | 864.99M | 848.76M | 888.44M | 427.09M | 439.15M | 454.91M | 458.60M | 441.25M | 415.44M | 460.63M | 416.63M | 446.75M | 472.96M | 492.95M | 482.23M | 486.03M | 489.92M | 491.01M | 500.58M | 506.61M | 495.10M | 504.30M | 511.16M | 458.36M | 468.84M | 492.88M | 476.20M | 487.78M |
| Operating Income | 140.96M | 151.13M | 150.96M | 124.23M | 147.78M | 156.89M | 142.78M | 106.04M | 121.90M | 126.43M | 125.70M | 99.66M | 122.39M | 104.21M | 105.55M | 39.99M | 43.05M | 48.57M | 40.14M | 10.80M | 34.56M | 20.46M | 32.30M | 26.10M | 50.02M | 58.79M | 39.11M | 50.16M | 47.39M | 30.04M | 48.50M | 40.27M | 15.89M | -157.72M | 33.83M | 32.10M | 59.87M | 68.05M | 41.66M | 56.92M |
| Net Income | 84.13M | 90.78M | 92.70M | 67.90M | 82.43M | 96.51M | 78.08M | 54.69M | 63.70M | 65.88M | 136.10M | 63.43M | 79.41M | 65.58M | 60.21M | -242.87M | -8.24M | -1.26B | 9.33M | -18.71M | -672.44M | -41.04M | -64.30M | 17.64M | 35.01M | 30.80M | -21.19M | 27.14M | 30.73M | 14.21M | 28.28M | 21.39M | 4.04M | -153.03M | 19.44M | 20.74M | 39.26M | 71.71M | 29.57M | 39.84M |
| Diluted EPS | 0.90 | 0.97 | 0.99 | 0.73 | 0.89 | 1.04 | 0.84 | 0.59 | 0.69 | 0.71 | 1.46 | 0.68 | 0.85 | 0.72 | 0.68 | -2.81 | -0.10 | -15.15 | 0.11 | -0.22 | -8.03 | -0.49 | -0.76 | 0.21 | 0.41 | 0.36 | -0.25 | 0.32 | 0.37 | 0.17 | 0.34 | 0.26 | 0.05 | -1.84 | 0.23 | 0.24 | 0.46 | 0.84 | 0.36 | 0.49 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | 3.18B | 3.25B | 1.72B | 1.78B | 1.73B | - | 1.97B | 1.99B | 2.01B | 1.91B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.50B | 1.57B | 1.56B | 1.42B |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 467.03M | 421.56M | 454.34M | 493.70M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 267.03M | 263.71M | 270.66M | 262.62M |
| Operating Income | 242.03M | 288.93M | 312.91M | 355.39M | 389.52M | 452.13M | 513.00M | 557.87M | 571.69M | 454.89M | 248.39M | 171.76M | 98.13M | - | 200.00M | 157.85M | 183.68M | 231.09M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 156.70M | 29.89M | -28.37M | 274.22M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 39.70M | 42.08M | 40.74M | 35.97M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 81.37M | -48.36M | -101.34M | 216.43M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 18.81M | 12.05M | -2.27M | 51.04M |
| Net Income | 169.20M | 175.80M | 202.69M | 218.00M | 240.91M | 280.52M | 317.28M | 336.32M | 324.91M | 320.37M | 268.63M | -1.50B | -796.49M | - | 66.33M | -60.41M | -99.07M | 165.39M |
| Diluted EPS | 3.59 | 3.78 | 4.26 | 2.23 | 2.42 | 2.78 | 3.18 | 3.58 | 3.49 | 3.45 | 2.93 | -17.83 | -9.55 | - | 0.79 | -0.73 | -1.19 | 1.94 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 1.69B | 2.04B | 2.27B | 2.75B | 3.01B | 3.61B | 4.55B | 5.34B | 5.87B | 5.94B | 4.15B | 3.35B | 2.72B | 2.35B | 2.22B | 2.15B | 2.25B |
| Total Equity | 959.05M | 965.14M | 1.19B | 1.45B | 1.73B | 2.04B | 2.34B | 2.26B | 2.44B | 2.76B | 3.07B | 3.09B | 1.50B | 747.49M | 896.49M | 891.63M | 849.06M | 764.94M | 865.85M |
| Cash & Equivalents | 102.84M | 14.35M | 26.50M | 26.25M | 18.60M | 21.28M | 31.14M | 47.93M | 51.57M | 55.70M | 40.45M | 40.77M | 107.87M | 1.12B | 387.39M | 9.82M | 73.26M | 229.94M | 375.24M |
| Long Term Debt | - | - | - | - | - | - | 27.00M | 557.45M | 1.26B | 1.68B | 1.85B | 1.97B | 1.70B | 1.70B | 989.70M | 637.20M | 622.20M | 611.20M | - |
| Total Liabilities | - | - | 499.25M | 590.19M | 541.63M | 714.97M | 665.73M | 1.34B | 2.11B | 2.58B | 2.80B | 2.85B | 2.65B | 2.60B | 1.83B | 1.46B | 1.37B | 1.39B | 1.38B |
| Current Liabilities | - | - | 346.70M | 221.06M | 254.30M | 268.34M | 326.79M | 416.27M | 428.77M | 448.95M | 531.42M | 502.76M | 541.82M | 444.33M | 427.37M | 426.98M | 388.95M | 434.11M | 458.91M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 181.39M | 241.37M | 240.56M | 270.67M | 324.91M | 405.40M | - | - | 443.78M | 511.38M | 313.71M | 357.71M | 204.62M | 76.74M | 166.94M | 137.32M | 206.57M | 271.09M |
| Investing Cash Flow | -222.90M | -163.13M | -361.61M | -190.57M | -460.55M | -263.49M | - | - | -821.22M | -576.61M | -142.77M | 102.45M | 815.51M | -53.07M | -56.95M | -48.18M | -35.41M | -18.30M |
| Financing Cash Flow | -46.97M | -66.08M | 120.80M | -87.75M | 138.33M | -132.05M | - | - | 381.56M | 89.74M | -170.61M | -393.07M | -4.16M | -760.12M | -487.55M | -25.71M | -14.48M | -107.49M |
| Share Buybacks | 200.00M | - | - | - | - | 51.86M | 488.43M | 235.05M | 61.83M | 70.19M | 302.16M | 145.28M | 8.49M | 4.72M | 88.51M | 919.00K | 1.70M | 86.68M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 23.7% | 21.1% | 22.6% | 25.8% |
| Operating Margin % | - | - | - | - | - | - | - | - | 18.0% | 14.0% | 14.4% | 9.7% | 5.7% | - | 10.1% | 7.9% | 9.1% | 12.1% |
| Net Margin % | - | - | - | - | - | - | - | - | 10.2% | 9.8% | 15.6% | -84.2% | -45.9% | - | 3.4% | -3.0% | -4.9% | 8.6% |
| ROE % | 17.5% | 14.8% | 14.0% | 12.6% | 11.8% | 12.0% | 14.0% | 13.8% | 11.8% | 10.4% | 8.7% | -99.9% | -106.6% | - | 7.4% | -7.1% | -13.0% | 19.1% |
| ROCE % | - | 21.5% | 17.2% | 17.6% | 15.7% | 16.9% | 16.1% | 13.5% | 11.7% | 8.5% | 4.6% | 4.8% | 3.4% | - | 10.4% | 8.6% | 10.7% | 12.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 16.88% | 13.71M | $364.94M |
| 2 | Vanguard Portfolio Management LLC | 7.37% | 5.99M | $159.26M |
| 3 | Dimensional Fund Advisors LP | 5.19% | 4.22M | $112.30M |
| 4 | Vanguard Capital Management LLC | 4.46% | 3.62M | $96.33M |
| 5 | State Street Corporation | 4.35% | 3.53M | $94.02M |
| 6 | Victory Capital Management Inc. | 4.21% | 3.42M | $90.92M |
| 7 | Wasatch Advisors LP | 3.08% | 2.50M | $66.50M |
| 8 | Geode Capital Management, LLC | 2.74% | 2.23M | $59.23M |
| 9 | American Century Companies Inc | 2.70% | 2.19M | $58.33M |
| 10 | Fuller & Thaler Asset Management Inc. | 2.12% | 1.72M | $45.81M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MD
Mednax Stock Price Forecast. Should You Buy MD? - StockInvest.us
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE1BQmw2TGFYeVFMTTlJaUdmMl9GeTVsUHlXN1VCN09ReV9uYzNVY0dxNGZ0b0ZqUDM0TFJsdnRZOUlzbTlWQ2c?oc=5" target="_blank">Mednax Stock Price Forecast. Should You Buy MD?</a> <font col…
Pediatrix Medical Group (MD) Up 3.4% Since Last Earnings Report: Can It Continue? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxQcUtwSHA0cVJwa2Y2cktnUTdJUTVUbDZOUTV5X08zMTQ4UTlBbTlaT05ReEVwOWJXRHNIc0xJVlVUR3cyOUtWakVzSjVicV9mWUtKWlpzc0c1N2VZWkFIalQ3ODhxSExuTHFHaW9nendTMHZNYlpwRllEMFJwX0JGZlNyOGwzMlQ0RG0yeH…
One holder owns 5.15% of Pediatrix (NYSE: MD). The latest filing corrects details, not the stake. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxPN014VFlCN1o1M3NVVDE0WllydTFuaDl0ZmhlS2tLYWNGcFc2SEpBTGxtZVJyNlFobWxWTHNCTE01cHY4SkFOaUkweHl3SVFReFc3blk0Ni1wOW5MUVBKZFY0a1daaFJjMjZuRmswdUlPeWpjM1MwUmloNkZyUEFjbWlvMXdYYjV3ak4tNG…
Charles Schwab MD Neesha Hathi sells $346k in stock - Investing.com
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxQQ1NOUXdqNWQzZnFvVXBSZmdNalpiU09KNV91THdFVHJVOGlJbGR3YURZd2QyUmY2ZENmQ2ktanFQRkR0WHM1T3UzS3FfbWZBclI1RWdjVVlIVmJWMlUzdTRUM0lqOFFQbDBfYWZtc1FjQmNDT1dwQW5BeDBiWmFZNENlS0hZdWFxc2h0NS…
Pediatrix Medical Group (MD) is a Top-Ranked Growth Stock: Should You Buy? - Eastern Progress
<a href="https://news.google.com/rss/articles/CBMi5wFBVV95cUxQZjN3UVB1S0RhR2FUY1E4SnpuOHAxbTNFaFk0VXR6YWRrVU1rMl9BMlV3T3I3dEMtMC1tRUloR1Q5NGdhWTV5N2RkSXdPVExwVjJWNDc0VF9pRFpWeDJBaVotTXR4VkQzYlVaRWRjLTFsR1FfTE1jNEwwNXFCWkxEcTJIYnlBZkI0Q0RVcn…
Why Pediatrix Medical Group (MD) Shares Are Trading Lower Today - StockStory
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxPUkJHVTFaSk9GaTA4Mi1PLWxNRF9vNnpqdFAtbExUNVJtSHJpMDJxVm9Db1gtQy1wSDdjbVZ4bWM3LXF6OTBJeGZuRHIzdFVjY3FkVHJPMTFJUFRzQlhPU0JnbDN4X3M1aWRQLTFJR3hacVgzQTNWU2ZFVkhwM2d1Q1hhRklNTFZwYnJ4OV…
MD — Frequently Asked Questions
What is the current share price of Pediatrix Medical Group, Inc. (MD)?
As of 2026-09-07 16:24 PDT, Pediatrix Medical Group, Inc. (MD) trades at $27.03 on NYSE. Its 52-week range is $15.50 to $27.39.
What is the market capitalisation of MD?
Pediatrix Medical Group, Inc. (MD) has a market capitalisation of $2.20B on NYSE.
What is the P/E ratio of MD?
MD trades at a trailing price-to-earnings (P/E) ratio of 12.93. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 2.47.
What is the return on equity (ROE) of MD?
MD has a return on equity (ROE) of 20.39%. Its return on capital employed (ROCE) is 12.93%.
Is MD a good stock to buy?
This page provides a data-driven analysis of Pediatrix Medical Group, Inc. (MD), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.